AbSci Corporation (ABSI)

I don't post hate. I only post reliable honest opinion. And I believe this is a garbage ticker.

Hello All:
Please take the time to review Helloman1's last 50 or 100 posts.
1. every post is mean spirited and full of hate
2. no posts are positive or encouraging.
we may conclude that this person is bitter and very unhappy in life.
throwing negativity and spewing harsh words is a sign of bigger things going on in (his) life.
3. Let's keep this in mind, ignore all of his posts, and feel sorry for this (pre dementia/ bi-polar/ shitzophrenic) loser.

Thank you for your attention to this matter.👍️

Stay away from this garbage.

ABSI THE BIO BEAST A BEASTVILLE...WEEKLY SMASH AND GRAB BREAK OUT

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026

Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option award has an exercise price of $4.92 per share, the closing price of Absci’s common stock on the Nasdaq Global Select Market on May 1, 2026 the (“Grant Date”). The stock option has a 10-year term and vests over four years, and 25% of the shares subject to the option vest and become exercisable on the one-year anniversary of the Grant Date and the remaining 75% of the shares subject to the option vest and become exercisable in 36 approximately equal monthly installments thereafter such that the shares underlying the option granted to the new employee will be fully vested on the fourth anniversary of the Grant Date, subject to the new employee’s continued service with Absci on each such date (subject to the terms and conditions of the Inducement Plan and the option award agreement covering the grant).

About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

Link article

$ABSI 🗞️

ABSI the bio beast that nobody is talking about

BIO BEAST BEASTING THROUGH BEASTVILLE

ABSI time for this bio to shine once again

I saw good news in report. 201 advancing. Good spot to.be in

40 million share short 18 days to cover last month it was 11 there's only about 40 million available shares to trade 80% close to of the 150 million are held by institutions which I'm sure some are leveraged short. Technically we're a 100% shorted. I'm holding 32,000 shares and I'm not selling until I hit six

Short interest. Ridiculous 25% of shares.
Have some good news please!

Someone tell GameStop boys. Lol

ABSI. Beautiful close to exit.

ABSI. Beautiful close. One more push!

ABSI. Bios hot breaking on weekly

ABSI. Bios hot breaking on weekly

ABSI. Bios hot breaking on weekly

$ABSI: With Oracle related news this Morning.... now $2.50

Remember....... today is 9/11


LIFE IS FLEETING.

Now........ hug your loved ones.... be kind............ AND MAKE SOME MEGA MONEY !!!!!!!!!


GO $ABSI

Short squeeze??? Looks good for one

Share Structure & Short Metrics
Outstanding shares: ~127.6?M

Float (public shares available): ~111.5?M StockAnalysis+11MarketBeat+11Seeking Alpha+11

Short interest: ~32.1?M shares, which is 28.8% of float (or ~25% of total shares) MarketBeat+1MarketBeat+1

Days to cover: ~9–10?days (varies by source: ~9.9 from MarketBeat, ~8.7 from StockAnalysis, ~6.7 from Fintel/Benzinga) Fintel+3MarketBeat+3Benzinga+3

Short interest trend: A ~23% increase in short interest in June, from ~26?M to ~32?M shares StockAnalysis+2MarketBeat+2Reddit+2

🔍 What This Means for a Possible Short Squeeze
A short squeeze is more likely when:

High short interest as percentage of float (=20%)

Elevated days to cover ratio (=5 days)

Catalysts like positive news or spikes in buying volume

ABSI checks the first two boxes:

Nearly 29% short float—substantially high

8–10 days to cover, indicating shorts would take a long time to unwind

Add in several bullish signals:

AI/ML-driven drug discovery partnerships (e.g., with AMD, Merck, AstraZeneca) Fintel+2Wikipedia+2Reddit+2MarketBeatBenzinga+3MarketBeat+3Fintel+3Wikipedia+5Reddit+5MarketBeat+5Yahoo Finance+10Reddit+10MarketBeat+10

Recent analyst upgrades (Needham, HC Wainwright, Guggenheim) with $7–$10 price targets MarketBeat

If ABSI experiences a strong positive catalyst or sharp price uptrend, the short sellers could be forced to scramble, buying to cover—a textbook setup for a short squeeze.

⚠️ Considerations & Risks
Volatile stock (high beta ~2.0–2.5)—price moves can be exaggerated Reddit+13Fintel+13Newser+13

A squeeze isn't guaranteed—market momentum and broader investor sentiment heavily influence outcomes

Catalyst-dependent—without a strong spark (earnings beat, major partnership, or takeover buzz), the squeeze may not materialize

✅ Bottom Line
ABSI has the classic technical setup for a short squeeze: very high short float, lengthy days to cover, and ongoing bullish interest. If positive news or a surge in buying pressure emerges, a squeeze could follow. But absent that catalyst, the stock may just meander or pull back, even though it's primed structurally.

Black Rock has been ringing the bell. Increase from five percent to over 6%, this quarter . I wonder what they know.

Patience is key with this one

It hasn't woken up yet, but the alarm is ringing. It only takes time..

ABSI MONSTER

GAPPED UP AH...BEAST!

Can it go to $60 next week like TEM or HIMS?

ABSI READY FOR 6.00

ABSI TRENDTRADE WEEKLY BREAK OUT

ABSI NEXT AI CANCER PLAY...MONSTER IN THE MAKING

ABSI: Clueless about it, since back then!! (THANKS for heads-up!!)

ABSI nice day $4s

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

https://www.technologynetworks.com/drug-discovery/articles/how-is-ai-being-used-in-drug-discovery-394789

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30:00 AM ET, 01/10/2025 - GlobeNewswire

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”

Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.

“At Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. “This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”

This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics

ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease.Absci Corporation (ABSI) announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.Tourmaline Bio (TRML) announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board.

AMD is investing $20 million in AI drug startup Absci , which will use AMD chips and software

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.

ABSI: I'm in --- nice deal with AMD!!

3rd quarter results Nov. 12, fyi ANT

2025 gettin' closer, ANT

Approachin' the end of the 6 month tradin' channel, gets interestin' now, fyi imvho ANT

C
A prescription drug bottle filled with 0s and 1s to represent binary code.Francis Scialabba
CFOs are embracing AI, experimenting with new use cases for it throughout the finance function. But some CFOs are tapping the potential of the technology in other ways. At biotech firm Absci, researchers are using AI to develop drugs to treat cancer. (We’re not saying that to make your Claude-drafted emails look bad, we promise.)

Absci’s CFO and CBO, Zach Jonasson, spoke with CFO Brew about how AI is allowing the company to create and test new antibodies faster—and cheaper—than ever before.

Absci uses E. coli—yes, the same bacteria that can give you some nasty infections—to manufacture antibodies that can be used in a variety of therapies. Using a process called “high throughput screening,” it then tests the antibodies, and it patents therapies containing the most promising ones.

Even before ChatGPT burst onto the scene, Absci saw potential in AI. Through its testing of antibodies, the company generated large amounts of data, which it realized could be used to train an AI. In 2021, it acquired a deep learning company called Denovium, which became “the nucleus” that it built a proprietary AI around, Jonasson said.

ABSI under $5

ABSI three month chart

Been 1 year since thus post and what a nice investment. Up 105% I'll take that all day and year long.

It will only take one success to be multi millions

It only takes one success..
Now we're in the cancer realm
My call 8.59 before end of year

touchin' resistance, anyday now imfho ANT

Canada: only 2 things i keep in mind: golden Maple leafs and a master chartist, a magic combo, ANT

moderate volume last few tradin' days but holdin' onto that nice area on the chart, ANT

testin' resistance for the 5th time, this puppy wants to move imvho ANT

imo now it breaks that first resistance at 4,50 are we'll temporarily be hooverin' back to the 50ma area, imo and fyi ANT